Recent increases in drug prices have become a central issue for consumers, media, and Congress. This panel, which includes WilmerHale Partner Mark Ford, will address the causes of these increases and the role of competition law in this arena. Why do we see price spikes? What if any role does competition law play to prevent price spikes? If price spikes are not subject to antitrust enforcement, what is the role for public policy?